Portfolio Diagnostic Report
A review of ten engagements across deep-science Indian ventures
A review of ten engagements across deep-science Indian ventures: the structural gaps between scientific merit and capital readiness, and the interventions applied to close them.
Reporting period FY2024 – FY2026 · Final as of June 2026
Cross-Portfolio Findings
What was true across all ten engagements.
Founding teams without a financial model at engagement
Every company reviewed had either no financial model, or a production/technical model with no revenue or unit-economics structure, prior to Ezeseed's engagement.
Cases requiring cap table or legal entity correction
Including IP held by individuals rather than corporate entities, unincorporated partnerships, and founder equity splits inconsistent with institutional investment standards.
Cases where the original go-to-market model was structurally unscalable
Most frequently a direct-to-consumer or direct-to-farmer model, later replaced with a B2B or B2B2C channel structure.
Cases requiring international PCT patent filing prior to grant or investor submission
India-only patent protection was insufficient for grant bodies and investors requiring jurisdiction-specific IP coverage as a funding precondition.
Company identities, founder names, and identifying institutional affiliations are withheld or generalised throughout. Sector classification, technology description, trial and pilot data, financial figures, and capital outcomes are presented as recorded in Ezeseed's internal engagement files. This does not constitute investment advice, and the outcomes described should not be construed as representative of expected results for any prospective engagement. Capital formation depends on technology quality, market timing, team composition, and investor relationships in addition to advisory intervention.